Verified employee & interview reviews

Glenmark Reviews

Mumbai, Maharashtra

—/ 5

0 reviews

Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, the company went public in India in 1999. Under the long-standing leadership of Chairman and Managing Director Glenn Saldanha, Glenmark has transitioned from a domestic branded generics business into a highly research-driven, global organization. The company's strategic vision focuses on a dual mission: pioneering innovative, breakthrough therapies and expanding global access to high-quality, affordable essential medicines. The company operates extensively across more than 80 countries, with a commercial presence spanning major regulated and emerging markets, including India, North America, Europe, Latin America, and rest of the world. Its vast global manufacturing infrastructure consists of over 14 state-of-the-art facilities located across India, the United States, Argentina, and the Czech Republic. Publicly traded on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker GLENMARK, the company reported a consolidated revenue of approximately ₹13,321 crore (US$1.4 billion) and a net income of ₹1,047 crore (US$110 million) for the fiscal year ending March 31, 2025. Glenmark’s commercial and research operations are broadly categorized into generics, specialty drugs, and over-the-counter (OTC) segments. Its core specialty and innovation framework is deeply concentrated across three pivotal therapeutic areas where clinical needs remain highly significant: Dermatology, Respiratory, and Oncology. In dermatology, Glenmark maintains a foundational strength, leveraging decades of category leadership to treat complex chronic conditions such as eczema, psoriasis, and severe fungal infections. Its respiratory franchise stands out as one of the most advanced in the industry, offering proprietary delivery systems like Dry Powder Inhalers (DPI) and Metered Dose Inhalers (MDI). A prime example of its innovation in this segment is Ryaltris, a first-of-its-kind fixed-dose combination nasal spray for allergic rhinitis, which has been commercialized in dozens of countries worldwide. To accelerate its proprietary drug discovery pipeline, Glenmark operates through its global innovation arm, Ichnos Glenmark Innovation (IGI). Formed to consolidate small-molecule and biologics research, IGI utilizes cutting-edge proprietary platforms to advance a specialized oncology pipeline, which includes novel trispecific antibodies designed to treat hematological malignancies like multiple myeloma as well as solid tumors. Glenmark regularly secures strategic global partnerships with top-tier biopharmaceutical companies—such as Pfizer, Hikma, Menarini, and AbbVie—to co-develop, license, and distribute its high-potential molecules. Emphasizing financial resilience alongside scientific rigor, the company has recently focused on key strategic initiatives to deleverage its balance sheet, optimize operations, and expand its specialty medicine footprint across global markets.